Company news
Emergent Biosolutions Inc. (NYSE:EBS) news
Every Emergent Biosolutions Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
August 5, 2026
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
July 22, 2026
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equi...
May 28, 2026
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
May 18, 2026
Emergent BioSolutions Reports First Quarter 2026 Financial Results
April 30, 2026
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox ...
April 30, 2026
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, S...
April 29, 2026
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in ...
April 28, 2026
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
April 16, 2026
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone P...
April 9, 2026
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Ov...
April 7, 2026
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
April 2, 2026
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Govern...
March 25, 2026
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
March 3, 2026
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
February 26, 2026
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leade...
February 26, 2026
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
February 12, 2026
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 12, 2026
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Car...
January 14, 2026
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transforma...
January 12, 2026
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department o...
January 8, 2026
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
January 8, 2026
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
January 7, 2026
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
December 12, 2025
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasi...
November 18, 2025
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
November 12, 2025
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
October 29, 2025
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
October 28, 2025
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
October 8, 2025
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with ...
September 24, 2025
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
September 19, 2025
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and S...
September 15, 2025
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Govern...
September 9, 2025
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax ...
September 2, 2025
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International O...
August 29, 2025
Emergent BioSolutions to Participate in Upcoming Investor Conferences
August 27, 2025
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Aware...
August 21, 2025
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
August 6, 2025
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
July 28, 2025
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
July 28, 2025
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
July 15, 2025
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGI...
July 8, 2025
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overd...
July 2, 2025
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equin...
June 23, 2025
Emergent BioSolutions Announces Addition to Russell 3000® Index
June 20, 2025
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to ...
June 5, 2025
Emergent BioSolutions Reports First Quarter 2025 Financial Results
May 7, 2025
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario M...
May 1, 2025
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
April 22, 2025